Highlights Reviva Pharmaceuticals Holdings, Inc.

Equities

RVPH

US76152G1004

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-10 EDT			5-day change	1st Jan Change
1.87 ^USD	-12.62%		-41.56%	-63.69%

04-15	Reviva Pharmaceuticals Holdings, Inc. Gains Alignment with U.S. Food and Drug Administration on its Registrational Phase 3 Program for Brilaroxazine in Schizophrenia	CI
04-15	Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Reviva Pharmaceuticals Holdings, Inc. Gains Alignment with U.S. Food and Drug Administration on its Registrational Phase 3 Program for Brilaroxazine in Schizophrenia	04-15	CI
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-15	CI
Reviva Pharmaceuticals to Seek Acquisitions	11-16	CI
Reviva Pharmaceuticals Holdings Q3 Loss Widens	11-14	MT
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Reviva Pharma's schizophrenia drug succeeds in late-stage study	23-10-30	RE
Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia	23-10-30	CI
Reviva Pharmaceuticals Holdings, Inc. Announces Enrollment Completion for Pivotal Phase 3 Recover Study for Brilaroxazine in Schizophrenia	23-08-17	CI
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Reviva Pharmaceuticals Holdings, Inc. Announces 80% Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia	23-06-22	CI
Reviva Pharmaceuticals Holdings, Inc Joins Webull Corporate Communications Service Platform	23-05-19	CI
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Reviva Pharmaceuticals Presents Foundational Preclinical Data on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual SOBP and Publication in Medical Research Archives	23-05-01	CI
Fed Rate Increase Drags Exchange-Traded Funds, Stock Futures Lower Premarket Thursday	22-12-15	MT
Reviva Pharmaceuticals Holdings, Inc. Announces Positive Safety Data from Drug-Drug Interaction Clinical Study of Brilaroxazine	22-12-15	CI
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Reviva Pharmaceuticals Announces Global Enrollment Update for Pivotal Phase 3 Recover Study Evaluating Brilaroxazine for Schizophrenia	22-10-31	CI
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Reviva Pharmaceuticals Holdings, Inc. Provides Update on Clinical Development Pipeline	22-07-27	CI
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Reviva Pharmaceuticals Holdings, Inc.

Equities

RVPH

US76152G1004

Highlights

Filters